Compare VALU & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VALU | IMRX |
|---|---|---|
| Founded | 1931 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 341.6M | 313.8M |
| IPO Year | 1995 | 2021 |
| Metric | VALU | IMRX |
|---|---|---|
| Price | $40.51 | $3.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $17.17 |
| AVG Volume (30 Days) | 1.4K | ★ 625.2K |
| Earning Date | 09-14-2026 | 11-11-2026 |
| Dividend Yield | ★ 3.15% | N/A |
| EPS Growth | 4.55 | ★ 37.75 |
| EPS | ★ 0.50 | N/A |
| Revenue | ★ $36,257,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $89.58 | ★ N/A |
| Revenue Growth | ★ 1.08 | N/A |
| 52 Week Low | $32.00 | $3.74 |
| 52 Week High | $44.79 | $8.48 |
| Indicator | VALU | IMRX |
|---|---|---|
| Relative Strength Index (RSI) | 67.77 | 24.84 |
| Support Level | $36.31 | N/A |
| Resistance Level | N/A | $5.32 |
| Average True Range (ATR) | 1.25 | 0.17 |
| MACD | 0.44 | -0.05 |
| Stochastic Oscillator | 83.64 | 6.57 |
Value Line Inc is a U.S based company. It produces investment periodicals based on underlying research and makes available copyright data, including a ranking system and other information, to third parties under written agreements for use in third-party managed and marketed investment products and for other purposes. The company markets its products under brands including Value Line, the Value Line logo, The Value Line Investment Survey, Smart Research, Smarter Investing, and The Most Trusted Name in Investment Research. Its only operating segment is Publishing.
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.